Gonadorelin Trial S1207 Status Updated: Active, Not Recruiting

On October 23, 2026, the clinical trial registry listed an updated status for the Phase 3 study known as S1207. The trial, titled "S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer," involves gonadorelin as part of the hormone therapy regimen being studied. The study's current status is active, not recruiting, meaning enrollment has concluded but participant follow up or other trial activities continue. This is a Phase 3 trial, identified under registry number NCT01674140. The update reflects only the trial's status as of the listed date. No results, outcomes, or efficacy data were included in this status update. The trial compares hormone therapy alone against hormone therapy combined with everolimus in patients with breast cancer, but this brief does not reflect any findings from that comparison. Readers should note that an active, not recruiting status indicates the trial is ongoing in some capacity but is no longer accepting new participants. For additional background on gonadorelin, including its approved regulatory status and general information, readers can refer to the compound overview.